ATCC scientists say AI models that predict antibiotic resistance from genomes need authenticated strains, paired MIC data and shared benchmarks.
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
For years, many small-molecule teams have treated comprehensive Absorption, Distribution, Metabolism and Excretion (ADME) profiling as a lead-optimization step. That is, it serves as a place to spend heavily once a lead series has already emerged. Now, Ginkgo Datapoints, Tangible Scientific and Inductive Bio are betting that AI, automation and tighter compound logistics can move…
Immunai’s digital ‘plumbing’ keeps AstraZeneca coming back
Immunai, a startup building a foundation model of the human immune system, has expanded its oncology collaboration with AstraZeneca for the third time. Immunai is eligible to receive up to $37.5 million over 2026 and 2027 under the new agreement, which extends its AMICA-OS platform deeper into AstraZeneca’s clinical development pipeline. The two companies began…
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
Amazon Web Services today launched Amazon Bio Discovery, an application that routes AI-designed antibody candidates directly to DNA Synthesis firm Twist Bioscience and the techbio Ginkgo Bioworks for synthesis and testing, with results flowing back into the same interface that generated them. AWS launched Amazon Bio Discovery with Bayer, the Broad Institute, Memorial Sloan Kettering…
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical R&D is at an inflection point. Consider that small molecules accounted for 65% of FDA novel drug approvals in 2025. That is a jump from 56% in both 2023 and 2024. The note that even as biologic sales are growing three times faster than their chemical counterparts and are projected to overtake them by…
How digital tools and AI are accelerating drug discovery
In traditional drug discovery, typical timelines for successful drugs stretch from 10 to 14 years, or sometimes even longer to bring a drug from discovery to approval. In addition to that, the cost of bringing a drug to market can range from hundreds of millions to multiple billions of dollars. In fact, the inflation-adjusted cost…
How stereo-correct data can de-risk AI-driven drug discovery
In drug discovery, the difference between a breakthrough and a breakdown can be as small as the twist of a bond. Stereochemistry, the three-dimensional arrangement of atoms, governs how otherwise identical molecules behave in the body: whether they bind the intended target, trigger off-targets, or get cleared in minutes rather than hours. “Shape really does…
See it in 1 second, act in 60: Eschbach’s take on how visual factories enable measurable decisions
Pharma plants are awash in data. There are myriad sources: MES for execution status, LIMS (QC results), process historians (equipment conditions), QMS (quality/deviations) to name just a few, but release decisions still stall when those sources disagree or lack an owner. To deal with the chaos, eschbach’s visual factory centers daily work on SQDCP boards…
As the pharma industry grapples with a talent shortfall, AI makes inroads in drug-safety workflows
It turns out that AI really is doing the work. At least a growing chunk of it. Artificial intelligence is spreading through the global workforce like wildfire, dwarfing the adoption pace of the internet, with a new Anthropic report citing Gallup research that 40% of U.S. employees now use AI at work. While the field…
ONI’s Aplo Scope achieves 20 nm imaging resolution, aims to cut drug target validation time
Oxford Nanoimaging (ONI) recently launched the Aplo Scope super-resolution microscope that pushes imaging precision to 20 nm. The Aplo Scope integrates lasers, optics, chemistry, and software in a compact footprint, helping researchers capture and analyze molecular interactions at the nanoscale. With its user-friendly design and portability, ONI aims to simplify super-resolution microscopy and potentially reduce…
Complexity’s counterpoint: Understanding protocol optimization
In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints and procedures across all trial phases and therapeutic areas. This trend, driven by the increasing sophistication of trial designs, is evident across trial phases and major therapeutic areas. Resulting in more endpoints and procedures on…
2024: The year AI drug discovery and protein structure prediction took center stage—2025 set to amplify growth
The global AI drug discovery market, valued around $1 to $1.7 billion in 2023, will be worth a multiple of that by the decade’s end. Analysts project the sector could be worth $9 billion or more. 2024 Nobel Prize in Chemistry Recipients: David Baker Demis Hassabis John Jumper Achievement: Computational protein design and structure prediction…
Drug development in 2025: 5 expert predictions cover synthetic data, hybrid trials and more
In 2024, we saw the expanded use of synthetic data and natural language processing transform drug discovery and development. In a batch of predictions published in December of 2023, one expert predicted that synthetic data was set to “take off” in drug research. In 2025, the pendulum could begin swinging back the other way, according…
PathAI launches AI tool for analyzing fibrosis in cancer tissue samples
The digital pathology firm PathAI has released PathExplore Fibrosis, an AI-based tool that analyzes fibrosis and collagen structures from H&E-stained whole-slide tissue images. The software quantifies fibrotic areas and collagen fibers from standard pathology slides, replacing specialized staining techniques and microscopy equipment. The tool processes large datasets of tissue images, designed to work with existing…
Scientists develop new machine-learning model to predict immunogenic neoantigens
Researchers at Cleveland Clinic’s Global Center for Immunotherapy, in collaboration with Bristol Myers Squibb, have published a comprehensive study on how the immune system remodels the tumor microenvironment in response to immune checkpoint therapy. This research represents the most detailed analysis of this process to date. Under the leadership of Timothy Chan, MD, PhD, Chair…
The future of RWD and RWE in healthcare decision-making: Applications of novel real-world data collection methods for healthcare decision-making
Real-world evidence and real-world data The use of real-world evidence (RWE) to support regulatory and reimbursement decision-making received increasing attention over the past decades. The US FDA provides a definition of RWE as “the clinical evidence about the usage and potential benefits and risks of a medical product”1. RWE can be used across the entire…
Intrepid Labs’ self-driving lab reimagines drug formulation
The pharma industry has long relied on tried-and-true drug formulation approaches sometimes rooted in trial and error, but this reliance on the familiar has created a bottleneck in the development of new and better medicines. University of Toronto Professor Christine Allen, Ph.D., co-founder and CEO of Toronto-based Intrepid Labs, points out that the traditional drug…
Inside BioXcel Therapeutics’ AI-driven drug reinnovation strategy
Friso Postma, vice president of AI for drug discovery at BioXcel Therapeutics, prefers the term “augmented intelligence” to “artificial intelligence.” His company uses AI tools to support human experts in drug repurposing efforts. Postma, who holds a PhD in signal transduction from the Netherlands Cancer Institute, transitioned to AI from wearable digital health devices. “I…
Demystifying deep learning: An accessible introduction to neural networks in health research and epidemiology
As machine learning and deep learning technologies advance thanks to advances in computation, algorithms and data availability, the possibilities of the technology continue to expand in medicine. While these AI-driven approaches have real potential, such systems demand large volumes of representative data, careful privacy and security scrutiny and thoughtful long-term strategic planning. In this Q&A, Kathryn…
Revised time series model forecasts Lilly’s Mounjaro sales to triple in 2024
Eli Lilly is experiencing meteoric growth in 2024, driven by surging demand for its metabolic therapies. In the first quarter, Lilly’s revenue jumped 26% year-over-year to $8.77 billion, propelled by strong sales of diabetes drug Mounjaro and weight loss treatment Zepbound Lilly also significantly raised its full-year 2024 outlook. The company now expects revenue in…
When will drug development have its ChatGPT moment? Inside ambitious AI initiatives at Sanofi and Medable
In episode 4 of AI Meets Life Sci, Kayleen Brown, managing editor at DeviceTalks and Brian Buntz, pharma and biotech editor, chat with Helen Merianos, Ph.D., head of R+D portfolio strategy at Sanofi and Michelle Longmire, MD, CEO of Medable. The focus? The two-fold application of AI in their respective companies’ technologies, both for scientific advancement…
Inside Amgen’s ATOMIC strategy to use ML to accelerate clinical trials
Amgen has developed a machine learning platform to slash clinical trial times through smarter site selection. Known as ATOMIC, short for Analytical Trial Optimization Module, the system crunches disparate datasets to predict optimal trial locations, expedite enrollment and trial processes. Early results indicate more than a two times increase in enrollment speed at ATOMIC sites.…
EDC fading in prominence as AI and cloud gain ground
In a year or two, the clinical trial industry may move beyond electronic data capture (EDC), a technology that has been the cornerstone of clinical data management for decades, projects Raj Indupuri, CEO of eClinical Solutions. Given the potential of electronic medical records (EMR) to feed directly into data infrastructure, the need for EDC may…
At AWS re:Invent, Pfizer exec frames digital as a core business strategy
In the midst of a global pandemic, Pfizer, under the leadership of its chief digital and technology officer Lidia Fonseca, achieved what was once thought impossible. The company, with the partnership of BioNTech, developed a COVID-19 vaccine in only 269 days, a process that traditionally would have taken 8 to 10 years. While prior research…
Genmab’s data-driven strategies speed up drug commercialization
Genmab’s senior vice president, global head of data science and AI, Hisham Hamadeh, describes the company’s journey to becoming “a data-driven decision-making company.” In one sense, there is little choice but to do so. “We’re swimming in data like never before. We’ve seen the volumes of data, the ability to compute on that data, and…
























